The FDA Posted Briefing Documents For Grails Galleri Test Review Ahead Of The Molecular And Clinical Genetics Panel Of The Medical Devices Advisory Committee That Is Being Held On September 23; Flags No Major Concerns For Co's Cancer Test
https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting
Share
Why It Matters
The FDA shared its review of Grails cancer blood test ahead of a meeting. The agency did not find any big safety problems with the test.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.